Fastner G, Sedlmayer F, Widder J, et al. - Researchers assessed long-term outcomes of patients suffering from hormonal receptor–positive breast cancer managed with breast-conserving surgery (BCS) and consecutive endocrine therapy (ET) with or without whole breast irradiation (WBI). Overall 869 patients underwent ET post-BCS which was randomly followed by WBI (n = 439, group 1) or observation (n = 430, group 2), within the 8 A trial of the Austrian Breast and Colorectal Cancer Study Group. WBI was administered up to a mean total dosage of 50 Gy (+/− 10 Gy boost) in conventional fractionation. Findings revealed that better local control and disease-free survival were achieved with WBI vs ET alone, following a median follow-up of 10 years. For local recurrence–free survival, the only negative predictors identified in this study were the omission of WBI and tumour grading, respectively.